Biolegend, 127633, Brilliant Violet 510™ anti-mouse Ly-6G Antibody, 50μg

Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, is expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.
50μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Ly-6G transfected EL-4J cell line.
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: While 1A8 recognizes only Ly-6G, clone RB6-8C5 recognizes both Ly-6G and Ly-6C. Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C15. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A815. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.416. Additional reported applications (for the relevant formats) include: immunohistochemistry9 of frozen sections10 and paraffin-embedded sections11, depletion4, 12-14, and spatial biology (IBEX)20,21. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for in vivo studies or highly sensitive assays (Cat. No. 127632, 127649, 127650, 127661 and 127662).
Application References(PubMed link indicates BioLegend citation): Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC) Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC) Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC) Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC) Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC) Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC) Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete) Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete) Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete) Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed Ma C, et al. 2012. J. Leukoc. Biol. 92:1199. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Deák P, et al. 2022. Cell Rep. 41:111563. PubMed Takimoto Y, et al. 2023. iScience. 26:106220. PubMed Barberio AE, et al. 2023. Bioeng Transl Med. 8:e10453. PubMed Tang C, et al. 2023. Nat Commun. 14:1493. PubMed Petenkova A, et al. 2023. Nat Commun. 14:2761. PubMed Koenig A, et al. 2022. Front Immunol. 12:791100. PubMed Dolfi B, et al. 2022. Cell Rep. 39:110949. PubMed Wanrooy BJ, et al. 2022. Immunol Cell Biol. 100:482. PubMed Drummer C, et al. 2023. Front Immunol. 14:1113883. PubMed Friedman D, et al. 2022. J Immunol. 208:1845. PubMed Postat J et al. 2018. Immunity. 49(4):654-665 . PubMed Devalaraja S, et al. 2020. Cell. 1098:180. PubMed Barberio AE, et al. 2020. ACS Nano. 14:11238. PubMed Bertocchi A, et al. 2021. Cancer Cell. 39(5):708-724.e11. PubMed Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed Amor C, et al. 2020. Nature. 583:127. PubMed Ratitong B, et al. 2021. Cell Reports. 35(7):109139. PubMed Devalaraja S, et al. 2020. STAR Protoc. 1:100188. PubMed Eisele AS, et al. 2022. Elife. 11:. PubMed Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed Guérin MV, et al. 2019. Nat Commun. 10:4131. PubMed Salvioni A et al. 2019. Cell Rep. 27(11):3254-3268 . PubMed Fennell LM, et al. 2020. EMBO J. 39:e103303. PubMed Lu X, et al. 2020. Sci Transl Med. 12:. PubMed Friedman DJ, et al. 2021. Cancer Immunol Res. 9:952. PubMed Kamp M, et al. 2016. PLoS One. 11: 0163750. PubMed Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed Uribesalgo I, et al. 2019. EMBO Mol Med. 11:e9266. PubMed Ding Y, et al. 2022. Cell Death Dis. 13:996. PubMed Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed Monaghan KL, et al. 2020. J Vis Exp. . PubMed Coronel MM, et al. 2020. Sci Adv. 6:eaba5573. PubMed Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed Sung PS, et al. 2022. JCI Insight. :. PubMed Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed Nicolas-Boluda A, et al. 2021. eLife. 10:00. PubMed Teijeira á, et al. 2020. Immunity. 52(5):856-871. PubMed Lee HN, et al. 2022. JCI Insight. 7:. PubMed Jones GS, et al. 2020. mSphere. 5:. PubMed Goldberg MF et al. 2018. Immunity. 49(6):1090-1102 . PubMed Kilgore AM, et al. 2020. J Immunol. 204:510. PubMed
RRID: AB_2562937 (BioLegend Cat. No. 127633)
Structure: A 21-35 kD GPI-anchorded membrane protein
Distribution: Expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes. The monoclonal antibody RB6-8C5 recognizes both Ly-6G and Ly-6C.
Cell Type: Granulocytes, Macrophages, Monocytes
Biology Area: Immunology, Innate Immunity
Antigen References: Fleming TJ, et al. 1993. J. Immunol. 151:2399.
Gene ID: 546644
UniProt: View information about Ly-6G on UniProt.org
Clone: 1A8
Regulatory Status: RUO
Other Names: Lymphocyte antigen 6 complex, locus G
Isotype: Rat IgG2a, κ